|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Chronic hepatitis C virus (HCV) infection remains a global health threat with 175 million carriers worldwide. Approximately 3% of the worldwide population is infected with the hepatitis C virus (HCV). Lymphoproliferative disorder (LPD) is a term that includes a wide spectrum of pathologies ranging from a minor expansion of a B-cell population (with no clinical significance) to an aggressive high-grade lymphoma. Such proliferations of B cells apparently can be triggered as a consequence of a chronic antigenic stimulation resulting from an HCV infection. A causative association between hepatotropic viruses, especially hepatitis C virus, and malignant B-cell lymphoproliferative disorders has been demonstrated utilizing epidemiologic data, biologic and molecular investigations, as well as clinical observations. These data indicate that hepatitis C virus may be responsible for the development of some malignant lymphoproliferative disorders. Occult hepatitis C virus infection (OCI) was first reported by Pham et al., (2004) who examined the expression of the HCV genome in the sera, PBMC, using a highly sensitive reverse transcription (RT)-PCR-nucleic acid hybridization (RT-PCR-NAH) assay. Occult hepatitis C virus infection (OCI), defined as the presence of HCV RNA in the liver and peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays. It can be found in both anti-HCV positive and negative cases.